Dr. Cho has served as the Principal Investigator of the NIDDK IBDGC DCC since 2003. She plays a lead role in setting scientific and operational priorities, assessing new sample and analytic approaches, and overseeing internal and external communication.
The Data Coordinating Center (DCC) of the NIDDK IBDGC plays a lead role in a) assessing and applying innovative research approaches in genetics and genomics to define pathophysiologic mechanisms, b) operationally unifying the NIDDK IBDGC and assuring rigor and reproducibility at scale, and c) facilitating collaboration with external investigators and groups to maximize the size and scientific value of existing datasets, provide complementary expertise, and develop the next generation of IBD investigators pursuing genetic, cellular and molecular understanding of IBD.
Aim 1: Optimize power and enhance pathophysiologic insight in clinical areas of unmet need in IBD byÂ
Coordinating, standardizing and tracking increased recruitment across the GRCs to substantially increased power to refine allelic effects may be achieved.Â
Integration with multi-omic ATAC + transcriptome single cell data may provide further refinement of association signals between Crohn’s disease and ulcerative colitis and across populations.Â
Complete mapping of sequence data for the NIDDK IBDGC lymphoblastoid lymphocyte repository from over 9000 patients will enable for broad use and dissemination and assist Ancillary studies.
Aim 2: To provide high-quality operational services targeted to the scientific objectives of the IBDGC, including:
Streamlined data collection, management and distribution;
Providing guidance in study design and data analysis;
Supporting Consortium governance, communication and administration.
Expanding the DCC’s infrastructure to accommodate new recruitment workflows, new GRC(s) and collaborators, and new analytic pipelines to accommodate the scale and richness of newly acquired data.
Enhance the IBDGC Data Commons and IBDGC website to promote and facilitate discovery and usage of our resources (including those accessible through the NIDDK Central Repository and dbGaP) throughout the IBDGC and IIIBDGC and by the broader research community.
Aim 3: In selected clinical scenarios of unmet medical needs, to enable longitudinal analyses prioritized by the NIDDK IBDGC Steering Committee. To scale and standardize multi-omic cellular data.
Performing multi-omic integration of the Crohn’s disease ileal resection cohort to predict recurrence and therapeutic response.
Adapting data collection workflows to capture new clinical priorities for prospective collections (eg. ulcerative colitis flares, and perianal Crohn’s disease)
Incorporating GRC analytic capacities in innovative endoscopy, radiology and pathology data
The DCC is piloting methods to facilitate recruitment in non-European populations using single IRBs, alternative reimbursement strategies, biobank-based and direct-to-patient recruitment approaches. The DCC leads a monthly coordinators’ meeting to communicate IBDGC priorities, assess progress and share effective recruiting and sample handling approaches across the Consortium.
The DCC is adding to its form-based methods for collecting phenotype data by using electronic medical records and diagnostic imaging and reports. IBDGC investigators are piloting image-based measurements beginning with radiology but likely expanding into both pathology and paraffin-based methods as well. Rapidly developing applications of multi-omic single cell technologies are a high priority, especially for their ability to provide insight into IBD physiology.
Common variant, GWAS-based data mapped to traits represents an important, foundation for further studies. Expansions of both chip and sequence-based cohorts will be finalized in 2021-2022 and published via dbGaP and the IBDGC Data Commons. The integration of African-based reference, common variant data substantially improves IBD trait prediction as an important basis for the expansion of non-European cohorts. Tissue-based, bulk RNAseq gene expression linked to important clinical inflection points has provided substantial mechanistic insight, especially when integrated with single cell data. Through the DCC, the IBDGC will utilize the Data Commons to increase the speed of analyses and data sharing in promotion of deeper collaboration.
The DCC organizes a rotating schedule of GRC presentations where work from junior investigators is encouraged. In 2020, the DCC initiated a webinar series focusing on data-intensive, translational investigators. Given a) the rapid rate of data expansion in scope and type, and b) the increasingly refined mining capacities of extant clinical collections, the opportunities for training and developing the next generation of translational researchers are highly promising.
Dr. Ron Do, Ph.D., is the Charles Bronfman Professor in Personalized Medicine at the Icahn School of Medicine at Mount Sinai. He is a full Professor with Tenure in the Department of Genetics and Genomic Sciences and founding Director of the Center for Genomic Data Analytics in The Charles Bronfman Institute for Personalized Medicine. He is a computational geneticist and data scientist interested in understanding the genomic, biological and clinical basis of human diseases. He has pursued this interest by developing and applying methods from human genetics, genetic epidemiology, statistical genetics, population genetics and scientific computing to large-scale human genotyping, sequencing, omics and clinical electronic health record datasets.
Dr. Gettler is leading efforts in genetic association, integration with gene expression and application of polygenic risk scores for trait prediction.
Ms. Sabic has extensive industry experience with Next Generation Sequencing, sample management, quality assurance processes and regulatory affairs. She is coordinating efforts and streamlining procedures for biospecimen management and processing, as well as overseeing patient recruitment.
Mr. Tastad is working to elevate analytical capabilities with back-end improvements, lean development, and application of advanced tool sets.
As a Clinical Research Coordinator Ms. Choi supports all aspects of the recruitment process to further increase our recruitment efforts. She also provides regulatory support for all our studies.